Home|Journals|Articles by Year|Audio Abstracts
 

Original Article

Med Arch. 2021; 75(3): 180-183


Protective Effect of Genistein on Cyclin D1 Expression in Malignant Ocular Melanoma Cells

Yasmin Sani Aprilliantina, Hera Dwi Novita, Elfina G Sadono, Rosy Aldina.




Abstract

Background: Ocular melanoma is a disorder that is rarely found but is deadly. Four tissues in the eye that can be attacked by melanoma include the uveal tract, conjunctiva, eyelids, and orbit. Uveal melanoma is the most common case, while melanoma conjunctiva is very rare. Objective: This study aimed to investigate the effect of giving genistein on cyclin D1 expression in malignant melanoma. Methods: When confluent, CRL1872 malignant melanoma cells will be divided into treatment groups, the group giving genistein dose 25 µM, the group giving genistein a dose of 50 µM, and the group giving genistein a dose of 100 µM. Cyclin D1 analysis was measured by immunofluorescence using confocal laser scan microscopy. Results: There was a significant increase in the expression of cyclin D1, in the group given genistein 25 µM and 50 µM (p < 0.05). For the administration of genistein dose of 100 µM, cyclin D1 expression decreased significantly compared to the control group (p < 0.05). Conclusion: It was concluded that genistein had a biphasic effect on cyclin D1 expression in malignant melanoma cells. Thus, genistein at the right dose can be a treatment of malignant melanoma.

Key words: ocular melanoma, soybeans, chemotherapy, biphasic effect.






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.